American Stroke Association Late-Breaking Science Report: Surgery, Stenting to Open Blocked Neck Arteries Similar in Safety, Efficacy, But Show Differences in Stroke, Heart Attack and Death Rates at Certain Ages

-- Younger patients had fewer cardiovascular events with an implanted stent, while older patients had fewer events with the surgical option.

-- Stroke and death rates in the study were the lowest ever reported in a clinical trial, researchers said.

SAN ANTONIO, Feb. 26 /PRNewswire-USNewswire/ -- The two major procedures for opening blocked neck arteries to restore blood flow to the brain proved similar in overall long-term safety and efficacy, but showed differences in stroke and heart attack in the weeks following the procedure, according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), funded by the National Institute of Neurological Disorders and Stroke with supplemental funding by Abbott, is the largest randomized clinical trial comparing the surgical approach (carotid endarterectomy) to the non-surgical approach (carotid stenting) to prevent stroke among patients with and without symptoms.

In endarterectomy, a surgeon cuts into the artery and carefully removes the obstructing plaque from the vessel wall. Surgeons have relied on endarterectomy for a half centuryto open narrowed carotid (neck) arteries. In stenting, which has been used for about 15 years, a balloon catheter is inserted into the artery to open it, and a metal mesh tube is left in place to keep the vessel open.

"We found that the two procedures were similar with regard to the study's primary endpoint —overall incidence of stroke, heart attack and death," said Thomas G. Brott, M.D., lead author of the study and professor of neurology and director for research at the Mayo Clinic campus in Jacksonville, Fla. "We also found that the rates of these events were low, and that safety for patients with and without symptoms was as good as any reported in any randomized carotid intervention trial."

Initial findings from CREST came from a median follow-up of about two-and-a-half years. Some patients have been followed for up to a total of four years.

Brott and his colleagues found that in the 30-day period following the procedure, the rate for stroke was 2.3 percent in the surgical patients and 4.1 percent in the stenting group. However, the heart attack rate was higher in the surgical group, 2.3 percent, compared to 1.1 percent in the stenting group. The difference in heart attack and stroke between the two groups was statistically significant, Brott said.

The study also found that the age of the patient made a difference in outcome. At approximately age 69 and younger, stenting results were slightly better, with a larger benefit for stenting, the younger the age of the patient. Conversely, for patients older than 70, surgical results were slightly superior to stenting, with larger benefits for surgery, the older the age of the patient.

In other words, younger patients had fewer events with an implanted stent, while older patients had fewer events with the surgical option, the researchers conclude.

CREST researchers enrolled two types of patients with a partial carotid blockage. Symptomatic participants had suffered a non-disabling stroke or a transient ischemic attack (TIA) within the previous six months. Asymptomatic patients had not had a stroke or TIA during the same time span.

Researchers randomized 2,502 patients— 35 percent were female and 9 percent minorities — to receive either endarterectomy or stenting at more than 100 North American hospitals. More than 80 percent of the participants had an artery blockage greater than 70 percent.

"It was not a healthy group with regard to risk for stroke, but we believe the group is very representative of patients with severe carotid artery disease," Brott said.

In addition, researchers found that symptomatic and asymptomatic patients, and males and females, had similar outcomes in the surgical and stenting groups.

Click here to view the perspective on the trial in a video interview with ASA Expert Perspective: Ralph Sacco, president elect of the American Heart Association.

Statements and conclusions of study authors that are presented at American Heart Association/American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...

(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...

(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...

(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...

(Date:12/8/2016)... Pa. , Dec. 8, 2016 Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...